The Southern African Journal of Infectious Diseases (SAJID), formerly called the Southern African Journal of Epidemiology and Infection (SAJEI), first appeared in 1985 as a joint publication of the Infectious Diseases Society of Southern Africa (IDSSA), the Sexually Transmitted Diseases Society of Southern Africa (STDSSA) and the Epidemiology Society of Southern Africa, the latter having subsequently been succeeded by the Public Health Association of South Africa (PHASA). Presently SAJID is published under the auspices of the Federation of Infectious Diseases Societies of South Africa which is an umbrella organisation incorporating IDSSA, STDSSA as well as the Infection Control Society of South Africa (ICASA), the National Antibiotic Study Forum (NASF) of South Africa, and the South African Society of Travel Medicine (SASTM).

Publications of SAJID centre round aspects of epidemiology and infection, particularly those of importance to the societies of FIDSSA. Topics around infection include clinical and epidemiological aspects of communicable diseases, laboratory diagnosis of infections, characterisation of infective agents by molecular techniques and the study of transmission patterns of pathogens in institutional and community settings. Other infection related studies cover surveillance of vaccine-controllable and other infectious diseases, drug susceptibility patterns of hospital-acquired and community-acquired pathogens and infection control strategies for the southern Africa region. SAJID also promotes greater collaboration between clinically oriented and laboratory-based divisions within the FIDSSA societies, and the establishment of quality assurance programmes and other measures to enhance and maintain standards of diagnostic and public health microbiology.

Scientific papers in the SAJID aim to advance the understanding of all aspects of epidemiology, public health, clinical microbiology and infection. The journal strives to promote research and exchange of information on specific areas of infectious diseases, medical microbiology and virology, covering fields of interest of the societies of FIDSSA and PHASA. Manuscripts describing research performed at southern African institutions and in southern African settings enjoy a high priority, as do health matters covering Africa and the developing world, as well as global issues such as malaria and other tropical diseases, tuberculosis, sexually transmitted infections and HIV/AIDS. The scope of interest of SAJID is wide but the journal aims to maintain and improve the standard of its publications.

Jardiance Declared Best International Pharmaceutical Product 2018

Jardiance Declared Best International Pharmaceutical Product 2018 Boehringer Ingelheim’s sodium-glucose co-transporter 2 (SGLT-2) inhibitor, Jardiance (empagliflozin), has been announced winner of the 2018 Prix Galien International Award in the category “Best...

Maternal mortality – Fact Sheet

Maternal mortality - Fact SheetMSD for Mothers     Global statistics1 • Every day, approximately 830 women die from preventable causes related to pregnancy and childbirth. • 99% of all maternal deaths occur in developing countries. • Maternal mortality is...

CIPLA LAUNCHES NEW TRIPLE-COMBINATION ANTIRETROVIRAL DRUG, REYDIN

Ahead of World Aids Day and as part of its continued commitment to ensuring access to quality, affordable antiretrovirals (ARV), Cipla is launching its new triple-combination ARV treatment for HIV in South Africa.

Empagliflozin proven to improve clinical outcomes in real world practice across a broad spectrum of cardiovascular risk

The most recent 2018 treatment recommendations from the American Diabetes Association are that, after considering drug specific and patient factors, treatment for people with atherosclerotic cardiovascular disease (ASCVD) should begin with lifestyle management and metformin and subsequently incorporate an agent proven to reduce major adverse cardiovascular events and/or cardiovascular mortality.

Skin protection range, Dexeryl, receives Allergy Foundation’s seal of approval

Partnership brings established international brand to South African consumers with complementary barrier and cleansing presentations for dry skins.

Wildcard SSL